Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology clinical practice guideline

Journal of Clinical Oncology

Volumn 31, Issue 6, 2013, Pages 794-810

  Flowers, Christopher R ^a   Seidenfeld, Jerome ^b   Bow, Eric J ^c   Karten, Clare ^d   Gleason, Charise ^a   Hawley, Douglas K ^e   Kuderer, Nicole M ^f   Langston, Amelia A ^a   Marr, Kieren A ^g   Rolston, Kenneth V I ^h   Ramsey, Scott D ⁱ  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d The Leukemia & Lymphoma Society   (United States)

^e Onc Heme Care   (United States)

^f DUKE UNIVERSITY   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CLINDAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIMICROBIAL THERAPY; ARTICLE; CANCER PATIENT; CANDIDIASIS; CONSENSUS; DISEASE DURATION; DISEASE SEVERITY; FEVER; HUMAN; MEDICAL HISTORY; MEDICAL SOCIETY; META ANALYSIS (TOPIC); NEUTROPENIA; NEUTROPHIL COUNT; OUTPATIENT CARE; PATIENT SAFETY; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC MYCOSIS;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; FEVER; HUMANS; MYCOSES; NEOPLASMS; NEUTROPENIA; OUTPATIENTS; PRACTICE GUIDELINES AS TOPIC; REVIEW LITERATURE AS TOPIC; TREATMENT OUTCOME;

EID: 84875728422     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.8661     Document Type: Article

References (158)

1. American Society of Clinical Oncology: American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimulating factors - Evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
2. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006 (Pubitemid 46638957)
3. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323-1332, 1993
4. Freifeld AG, Pizzo PA: The outpatient management of febrile neutropenia in cancer patients. Oncology (Williston Park) 10:599-606, 611-612, 1996; discussion 615-616
5. Bodey GP: The treatment of febrile neutropenia: From the Dark Ages to the present. Support Care Cancer 5:351-357, 1997 (Pubitemid 27402586)
6. Sundararajan V, Rubenstein EB, Rolston KV, et al: Controversies in new antibiotic therapy for ambulatory patients. Support Care Cancer 5:358- 364, 1997 (Pubitemid 27402587)
7. Hughes WT, Armstrong D, Bodey GP, et al: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751, 2002 (Pubitemid 34194843)
8. Link H, Bohme A, Cornely OA, et al: Antimicrobial therapy of unexplained fever in neutropenic patients: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 82:S105-S117, 2003 (suppl 2) (Pubitemid 37265297)
9. Tamura K: Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: Validation by the Japan Febrile Neutropenia Study Group. Int J Antimicrob Agents 26: S123-S127, 2005 (suppl 2); discussion S133-S140 (Pubitemid 41606722)
10. de Naurois J, Novitzky-Basso I, Gill MJ, et al: Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 21:v252- v256, 2010
11. Baden LR, Bensinger W, Casper C, et al: Prevention and treatment of cancer related infections: NCCN clinical practice guidelines in oncology (version 2.2011). Fort Washington, PA, National Comprehensive Cancer Network, 2011
12. Freifeld AG, Bow EJ, Sepkowitz KA, et al: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56-e93, 2011
13. Tam CS, O'Reilly M, Andresen D, et al: Use of empiric antimicrobial therapy in neutropenic fever: Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 41:90-101, 2011
14. Davis DD, Raebel MA: Ambulatory management of chemotherapy-induced fever and neutropenia in adult cancer patients. Ann Pharmacother 32: 1317-1323, 1998 (Pubitemid 29013356)
15. Rolston KV: New trends in patient management: Risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 29:515-521, 1999 (Pubitemid 29439944)
16. Castagnola E, Paola D, Giacchino R, et al: Clinical and laboratory features predicting a favorable outcome and allowing early discharge in cancer patients with low-risk febrile neutropenia: A literature review. J Hematother Stem Cell Res 9:645-649, 2000
17. Klastersky J: Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39:S32-S37, 2004 (suppl 1) (Pubitemid 38971473)
18. Bow EJ: Management of the febrile neutropenic cancer patient: Lessons from 40 years of study. Clin Microbiol Infect 11:24-29, 2005 (suppl 5) (Pubitemid 41348482)
19. Kern WV: Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis 42:533-540, 2006 (Pubitemid 43202527)
20. Chisholm JC, Dommett R: The evolution towards ambulatory and day-case management of febrile neutropenia. Br J Haematol 135:3-16, 2006 (Pubitemid 44337658)
21. Worth LJ, Lingaratnam S, Taylor A, et al: Use of risk stratification to guide ambulatory management of neutropenic fever. Intern Med J 41:82-89, 2011
22. Karthaus M, Carratalá J, Jurgens H, et al: New strategies in the treatment of infectious complications in haematology and oncology: Is there a role for out-patient antibiotic treatment of febrile neutropeniaChemotherapy 44:427-435, 1998 (Pubitemid 28468496)
23. van Tiel FH, Harbers MM, Kessels AG, et al: Home care versus hospital care of patients with hematological malignancies and chemotherapyinduced cytopenia. Ann Oncol 16:195-205, 2005 (Pubitemid 40309296)
24. Carstensen M, Sørensen JB: Outpatient management of febrile neutropenia: Time to revise the present treatment strategy. J Support Oncol 6:199-208, 2008 (Pubitemid 351836606)
25. Teuffel O, Ethier MC, Alibhai SM, et al: Outpatient management of cancer patients with febrile neutropenia: A systematic review and metaanalysis. Ann Oncol 22:2358-2365, 2011
26. Vidal L, Paul M, Ben-Dor I, et al: Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 4:CD003992, 2004
27. Vidal L, Paul M, Ben Dor I, et al: Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: A systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 54:29-37, 2004 (Pubitemid 39028964)
28. Lingaratnam S, Slavin MA, Koczwara B, et al: Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011: Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 41:75-81, 2011
29. Slavin MA, Lingaratnam S, Mileshkin L, et al: Use of antibacterial prophylaxis for patients with neutropenia: Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 41:102-109, 2011
30. Chrischilles E, Delgado DJ, Stolshek BS, et al: Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control 9:203-211, 2002 (Pubitemid 34657282)
31. Crawford J, Dale DC, Lyman GH: Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management. Cancer 100:228-237, 2004 (Pubitemid 38063629)
32. von Minckwitz G, Schwenkglenks M, Skacel T, et al: Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis. Eur J Cancer 45:608-617, 2009
33. Lyman GH, Dale DC, Friedberg J, et al: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study. J Clin Oncol 22:4302-4311, 2004 (Pubitemid 41185151)
34. Voog E, Bienvenu J, Warzocha K, et al: Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: Role of the tumor necrosis factor ligand-receptor system. J Clin Oncol 18:325-331, 2000 (Pubitemid 30056421)
35. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, et al: A predictive model for lifethreatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 37:351-360, 2000 (Pubitemid 30162545)
36. Cullen MH, Billingham LJ, Gaunt CH, et al: Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol 25:4821- 4828, 2007 (Pubitemid 350086487)
37. Hosmer W, Malin J, Wong M: Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer 19:333-341, 2010
38. Klastersky J, Paesmans M, Rubenstein EB, et al: The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-3051, 2000 (Pubitemid 30644129)
39. Gardner A, Mattiuzzi G, Faderl S, et al: Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol 26:5684-5688, 2008
40. Bow EJ: Infectious complications in patients receiving cytotoxic therapy for acute leukemia: History, background, and approaches to management, in Wingard JR, Bowden RA (eds): Management of Infection in Oncology Patients. London, United Kingdom, Martin Dunitz, 2003, pp 71-104
41. Bow EJ, Meddings JB: Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia 20: 2087-2092, 2006 (Pubitemid 44782833)
42. Ray-Coquard I, Borg C, Bachelot T, et al: Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 88:181-186, 2003 (Pubitemid 36255833)
43. Pettengell R, Schwenkglenks M, Leonard R, et al: Neutropenia occurrence and predictors of reduced chemotherapy delivery: Results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 16:1299-1309, 2008
44. Talcott JA, Finberg R, Mayer RJ, et al: The medical course of cancer patients with fever and neutropenia: Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148:2561- 2568, 1988 (Pubitemid 19048173)
45. Talcott JA, Siegel RD, Finberg R, et al: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322, 1992
46. Bow EJ, Kilpatrick MG, Scott BA, et al: Acute myeloid leukemia in Manitoba: The consequences of standard "7 - 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome. Cancer 74:52-60, 1994 (Pubitemid 24187609)
47. Schwenkglenks M, Jackisch C, ConstenlaM, et al: Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 14:901-909, 2006
48. Rubenstein EB, Peterson DE, Schubert M, et al: Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100:2026-2046, 2004 (suppl 9) (Pubitemid 38525884)
49. Sonis ST, Oster G, Fuchs H, et al: Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201-2205, 2001 (Pubitemid 32372323)
50. Bodey GP, Buckley M, Sathe YS, et al: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-340, 1966
51. Bodey GP, Rodriguez V, Chang HY, et al: Fever and infection in leukemic patients: A study of 494 consecutive patients. Cancer 41:1610-1622, 1978 (Pubitemid 8333322)
52. Blay JY, Chauvin F, Le Cesne A, et al: Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 14:636- 643, 1996 (Pubitemid 26051031)
53. Oguz A, Karadeniz C, Ckitak EC, et al: Which one is a risk factor for chemotherapy-induced febrile neutropenia in childhood solid tumors: Early lymphopenia or monocytopeniaPediatr Hematol Oncol 23:143-151, 2006 (Pubitemid 43170536)
54. Aapro MS, Cameron DA, Pettengell R, et al: EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433-2453, 2006 (Pubitemid 44442936)
55. Lalami Y, Paesmans M, Muanza F, et al: Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factorsA retrospective analysis. Ann Oncol 17:507-514, 2006 (Pubitemid 43329591)
56. Moreau M, Klastersky J, Schwarzbold A, et al: A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol 20:513-519, 2009
57. Aapro MS, Bohlius J, Cameron DA, et al: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8-32, 2011
58. Crawford J, Caserta C, Roila F: Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 21:v248-v251, 2010 (suppl 5)
59. Lyman GH: A comparison of international guidelines for the prevention of chemotherapyinduced neutropenia. Curr Opin Hematol [epub ahead of print on October 29, 2010]
60. Falagas ME, Vardakas KZ, Samonis G: Decreasing the incidence and impact of infections in neutropenic patients: Evidence from meta-analyses of randomized controlled trials. Curr Med Res Opin 24:215-235, 2008 (Pubitemid 351160254)
61. Cruciani M, Rampazzo R, Malena M, et al: Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis. Clin Infect Dis 23:795-805, 1996 (Pubitemid 26331127)
62. Engels EA, Lau J, Barza M: Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis. J Clin Oncol 16:1179-1187, 1998 (Pubitemid 28108756)
63. Cruciani M, Malena M, Bosco O, et al: Reappraisal with meta-analysis of the addition of Grampositive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 21:4127-4137, 2003 (Pubitemid 46606180)
64. Gafter-Gvili A, Fraser A, Paul M, et al: Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 4:CD004386, 2005
65. Gafter-Gvili A, Fraser A, Paul M, et al: Metaanalysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979-995, 2005 (Pubitemid 40840313)
66. van de Wetering MD, de Witte MA, Kremer LC, et al: Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: A systematic review of randomised controlled trials. Eur J Cancer 41:1372-1382, 2005 (Pubitemid 40826460)
67. Gafter-Gvili A, Paul M, Fraser A, et al: Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: Systematic review and metaanalysis. J Antimicrob Chemother 59:5-22, 2007 (Pubitemid 46017895)
68. Leibovici L, Paul M, Cullen M, et al: Antibiotic prophylaxis in neutropenic patients: New evidence, practical decisions. Cancer 107:1743-1751, 2006 (Pubitemid 44582942)
69. Imran H, Tleyjeh IM, Arndt CA, et al: Fluoroquinolone prophylaxis in patients with neutropenia: A meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 27:53-63, 2008 (Pubitemid 350197874)
70. Herbst C, Naumann F, Kruse EB, et al: Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Cochrane Database Syst Rev 1:CD007107, 2009
71. Ng ES, Liew Y, Koh LP, et al: Fluoroquinolone prophylaxis against febrile neutropenia in areas with high fluoroquinolone resistance: An Asian perspective. J Formos Med Assoc 109:624-631, 2010
72. Timmer-Bonte JN, Tjan-Heijnen VC: Febrile neutropenia: Highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors. Anticancer Drugs 17:881-889, 2006 (Pubitemid 44350607)
73. Bow EJ: Prophylaxis, in Kleinberg M (ed): Managing Infections in Patients With Hematological Malignancies: Contemporary Hematology. New York, NY, Springer/Humana Press, 2010, pp 259-308
74. Cornely OA, Ullmann AJ, Karthaus M: Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 101:3365-3372, 2003 (Pubitemid 36857916)
75. Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH: Posaconazole: An oral triazole with an extended spectrum of activity. Ann Pharmacother 42: 1429-1438, 2008
76. Gøtzsche PC, Johansen HK: Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 314:1238- 1244, 1997 (Pubitemid 27173908)
77. Kanda Y, Yamamoto R, Chizuka A, et al: Prophylactic action of oral fluconazole against fungal infection in neutropenic patients: A meta-analysis of 16 randomized, controlled trials. Cancer 89:1611- 1625, 2000
78. Gotzsche PC, Johansen HK: Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev 2:CD000026, 2002
79. Bow EJ, Laverdiére M, Lussier N, et al: Antifungalprophylaxisforseverelyneutropenicchemotherapy recipients: A meta analysis of randomizedcontrolled clinical trials. Cancer 94:3230-3246, 2002
80. Glasmacher A, Prentice A, Gorschluter M, et al: Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients. J Clin Oncol 21:4615-4626, 2003 (Pubitemid 46594036)
81. Robenshtok E, Gafter-Gvili A, Goldberg E, et al: Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: Systematic review and meta-analysis. J Clin Oncol 25:5471-5489, 2007 (Pubitemid 350232225)
82. Sepkowitz KA, Brown AE, Telzak EE, et al: Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 267:832- 837, 1992
83. Sepkowitz KA: Pneumocystis carinii pneumonia among patients with neoplastic disease. Semin Respir Infect 7:114-121, 1992
84. Sepkowitz KA: Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 17:S416-S422, 1993 (suppl 2) (Pubitemid 23322834)
85. Kamel S, O'Connor S, Lee N, et al: High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 51:797-801, 2010
86. Hashimoto K, Kobayashi Y, Asakura Y, et al: Pneumocystis jiroveci pneumonia in relation to CD4- lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy. Leuk Lymphoma 51:1816-1821, 2010
87. Green H, Paul M, Vidal L, et al: Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: Systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82:1052-1059, 2007 (Pubitemid 47357136)
88. Firpi RJ, Nelson DR: Viral hepatitis: Manifestations and management strategy. Hematology Am Soc Hematol Educ Program 375-380, 2006
89. Kohrt HE, Ouyang DL, Keeffe EB: Systematic review: Lamivudine prophylaxis for chemotherapy- induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 24:1003-1016, 2006 (Pubitemid 44386525)
90. Loomba R, Rowley A, Wesley R, et al: Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519-528, 2008 (Pubitemid 351665421)
91. Glenny AM, Fernandez Mauleffinch LM, Pavitt S, et al: Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev 1:CD006706, 2009
92. Sandherr M, Einsele H, Hebart H, et al: Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 17:1051-1059, 2006 (Pubitemid 43985238)
93. Centers for Disease Control (CDC), Infectious Disease Society of America (IDSA), American Society of Blood and Marrow Transplantation (ASBMT): Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 6:659-713; 715; 717-727, 2000; quiz 729-733
94. Management of herpes virus infections following transplantation. J Antimicrob Chemother 45: 729-748, 2000
95. Sullivan KM, Dykewicz CA, Longworth DL, et al: Preventing opportunistic infections after hematopoietic stem cell transplantation: The Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program 392-421, 2001
96. Tomblyn M, Chiller T, Einsele H, et al: Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant 15:1143-1238, 2009
97. Kunisaki KM, Janoff EN: Influenza in immunosuppressed populations: A review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 9:493-504, 2009
98. Pollyea DA, Brown JM, Horning SJ: Utility of influenza vaccination for oncology patients. J Clin Oncol 28:2481-2490, 2010
99. Gross PA, Gould AL, Brown AE: Effect of cancer chemotherapy on the immune response to influenza virus vaccine: Review of published studies. Rev Infect Dis 7:613-618, 1985
100. Brydak LB, Machala M: Humoral immune response to influenza vaccination in patients from high risk groups. Drugs 60:35-53, 2000 (Pubitemid 30601315)
101. Ring A, Marx G, Steer C, et al: Influenza vaccination and chemotherapy: A shot in the darkSupport Care Cancer 10:462-465, 2002 (Pubitemid 36056270)
102. Vilar-Compte D, Cornejo P, Valle-Salinas A, et al: Influenza vaccination in patients with breast cancer: A case-series analysis. Med Sci Monit 12: CR332-CR336, 2006 (Pubitemid 44186374)
103. Cheuk DK, Chiang AK, Lee TL, et al: Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev 3:CD006505, 2011
104. Goossen GM, Kremer LC, van de Wetering MD: Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev 2:CD006484, 2009
105. Gøtzsche PC, Johansen HK: Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev 2:CD002033, 2002
106. Vardakas KZ, Michalopoulos A, Falagas ME: Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: A meta-analysis of randomisedcontrolled trials. Br J Haematol 131:22-28, 2005 (Pubitemid 43899704)
107. Green H, Paul M, Vidal L, et al: Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 3:CD005590, 2007
108. Arrowood JR, Hayney MS: Immunization recommendations for adults with cancer. Ann Pharmacother 36:1219-1229, 2002 (Pubitemid 34755801)
109. Whitley RJ, Monto AS: Prevention and treatment of influenza in high-risk groups: Children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis 194:S133- S138, 2006 (suppl 2) (Pubitemid 44630957)
110. Fiore AE, Shay DK, Broder K, et al: Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 57:1-60, 2008
111. Fiore AE, Uyeki TM, Broder K, et al: Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 59:1- 62, 2010
112. Centers for Disease Control and Prevention (CDC): Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 60:1128-1132, 2011
113. Boyce JM, Pittet D: Guideline for hand hygiene in health-care settings: Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force - Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 51:1-45, 2002; quiz CE1-CE4
114. Siegel JD, Rhinehart E, Jackson M, et al: 2007 guideline for isolation precautions: Preventing transmission of infectious agents in health care settings. Am J Infect Control 35:S65-S164, 2007 (suppl 2) (Pubitemid 350213178)
115. Centers for Disease Control and Prevention: Guide to Infection Prevention for Outpatient Settings: Minimum Expectations for Safe Care, 2011. http://www.cdc.gov/HAI/pdfs/guidelines/standatds-ofambulatory- care-7-2011.pdf
116. Anderson K, Morris G, Kennedy H, et al: Aspergillosis in immunocompromised paediatric patients: Associations with building hygiene, design, and indoor air. Thorax 51:256-261, 1996 (Pubitemid 26088553)
117. Oren I, Haddad N, Finkelstein R, et al: Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: Before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 66:257-262, 2001 (Pubitemid 32210293)
118. Yonemori K, Takezako N, Nishimura K, et al: Fungal infection in neutropenic patients in a hospital during construction. Jpn J Infect Dis 55:126-127, 2002 (Pubitemid 35378926)
119. Raad I, Hanna H, Osting C, et al: Masking of neutropenic patients on transport from hospital rooms is associated with a decrease in nosocomial aspergillosis during construction. Infect Control Hosp Epidemiol 23:41-43, 2002 (Pubitemid 34157776)
120. Haiduven D: Nosocomial aspergillosis and building construction. Med Mycol 47:S210-S216, 2009 (suppl 1)
121. Eckmanns T, Ruden H, Gastmeier P: The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: A systematic review. J Infect Dis 193:1408-1418, 2006 (Pubitemid 43673389)
122. Maschmeyer G, Neuburger S, Fritz L, et al: A prospective, randomised study on the use of wellfitting masks for prevention of invasive aspergillosis in high-risk patients. Ann Oncol 20:1560-1564, 2009
123. Sugahara H, Mizuki M, Matsumae S, et al: Footwear exchange has no influence on the incidence of febrile neutropenia in patients undergoing chemotherapy for hematologic malignancies. Infect Control Hosp Epidemiol 25:51-54, 2004 (Pubitemid 38139846)
124. Moody K, Finlay J, Mancuso C, et al: Feasibility and safety of a pilot randomized trial of infection rate: Neutropenic diet versus standard food safety guidelines. J Pediatr Hematol Oncol 28:126- 133, 2006 (Pubitemid 43791808)
125. van Tiel F, Harbers MM, Terporten PH, et al: Normal hospital and low-bacterial diet in patients with cytopenia after intensive chemotherapy for hematological malignancy: A study of safety. Ann Oncol 18:1080-1084, 2007 (Pubitemid 47050500)
126. Scheid C, Hermann K, Kremer G, et al: Randomized, double-blind, controlled study of glycylglutamine- dipeptide in the parenteral nutrition of patients with acute leukemia undergoing intensive chemotherapy. Nutrition 20:249-254, 2004 (Pubitemid 38264378)
127. Klastersky J, Paesmans M, Georgala A, et al: Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129-4134, 2006 (Pubitemid 46622289)
128. Uys A, Rapoport BL, Anderson R: Febrile neutropenia: A prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555-560, 2004 (Pubitemid 39062546)
129. Cherif H, Johansson E, Bjorkholm M, et al: The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91:215-222, 2006
130. Klastersky J, Ameye L, Maertens J, et al: Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30:S51-S59, 2007 (suppl 1)
131. Uys A, Rapoport BL, Fickl H, et al: Prediction of outcome in cancer patients with febrile neutropenia: Comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care (Engl) 16:475-483, 2007
132. de Souza Viana L, Serufo JC, da Costa Rocha MO, et al: Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 16:841-846, 2008 (Pubitemid 351809802)
133. Hui EP, Leung LK, Mo F, et al: Evaluation of risk assessment tools and infectious aetiology in cancer patients with fever and neutropaenia in Hong Kong. Hong Kong Med J 16:34-37, 2010 (suppl 3)
134. (suppl 3) 134. Hui EP, Leung LK, Poon TC, et al: Prediction of outcome in cancer patients with febrile neutropenia: A prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Support Care Cancer 19:1625-1635, 2011
135. Ahn S, Lee YS, Chun YH, et al: Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer 19:1151-1158, 2011
136. Innes HE, Smith DB, O'Reilly SM, et al: Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: A prospective randomised controlled single centre study. Br J Cancer 89:43-49, 2003 (Pubitemid 36897933)
137. Hidalgo M, Hornedo J, Lumbreras C, et al: Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: A prospective, randomized clinical trial. Cancer 85:213-219, 1999 (Pubitemid 29031377)
138. Rapoport BL, Sussmann O, Herrera MV, et al: Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: Early hospital discharge vs. Standard In-patient care. Chemotherapy 45:466-476, 1999 (Pubitemid 29531418)
139. Malik IA, Khan WA, Karim M, et al: Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial. Am J Med 98:224-231, 1995
140. Innes H, Lim SL, Hall A, et al: Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: Feasibility and safety in routine clinical practice. Support Care Cancer 16:485-491, 2008 (Pubitemid 351502757)
141. Girmenia C, Russo E, Carmosino I, et al: Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia. Ann Hematol 86:263-270, 2007 (Pubitemid 46351401)
142. Elting LS, Lu C, Escalante CP, et al: Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606-611, 2008 (Pubitemid 351264355)
143. Del Prete SA, Ryan SP, Jacobson JS, et al: Safety and costs of treating neutropenic fever in an outpatient setting. Conn Med 63:713-717, 1999 (Pubitemid 30030642)
144. From the Immunocompromised Host Society: The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient - Report of a consensus panel. J Infect Dis 161:397-401, 1990
145. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock - 2008. Intensive Care Med 34:17-60, 2008
146. Paul M, Yahav D, Fraser A, et al: Empirical antibiotic monotherapy for febrile neutropenia: Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 57:176- 189, 2006 (Pubitemid 43160156)
147. Paul M, Yahav D, Bivas A, et al: Antipseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: Comparison of beta-lactams. Cochrane Database Syst Rev 11: CD005197, 2010
148. Paul M, Borok S, Fraser A, et al: Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev 3:CD003914, 2005
149. Vardakas KZ, Samonis G, Chrysanthopoulou SA, et al: Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: A meta-analysis of randomised controlled trials. Lancet Infect Dis 5:431-439, 2005 (Pubitemid 40846470)
150. Paul M, Soares-Weiser K, Grozinsky S, et al: Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 3:CD003038, 2003
151. Paul M, Soares-Weiser K, Leibovici L: Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: Systematic review and meta-analysis. BMJ 326: 1111, 2003
152. Furno P, Bucaneve G, Del Favero A: Monotherapy or aminoglycoside- containing combinations for empirical antibiotic treatment of febrile neutropenic patients: A meta-analysis. Lancet Infect Dis 2:231-242, 2002 (Pubitemid 34464753)
153. Furno P, Dionisi MS, Bucaneve G, et al: Ceftriaxone versus beta-lactams with antipseudomonal activity for empirical, combined antibiotic therapy in febrile neutropenia: A meta-analysis. Support Care Cancer 8:293-301, 2000 (Pubitemid 30430052)
154. Deaney NB, Tate H: A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients. J Antimicrob Chemother 37:975-986, 1996 (Pubitemid 26158784)
155. Dranitsaris G, Tran TM, McGeer A, et al: Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics 7:49-62, 1995
156. Sanders JW, Powe NR, Moore RD: Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: A meta-analysis. J Infect Dis 164:907-916, 1991
157. Freifeld A, Sankaranarayanan J, Ullrich F, et al: Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Support Care Cancer 16:181-191, 2008
158. Rubenstein EB, Rolston K, Benjamin RS, et al: Outpatient treatment of febrile episodes in lowrisk neutropenic patients with cancer. Cancer 71: 3640-3646, 1993 (Pubitemid 23152677)